Neoadjuvant-Intent Immunotherapy in Advanced, Resectable Cutaneous Squamous Cell Carcinoma

作者：Emily Kim, Emily S. Ruiz, Mia S. DeSimone, Sophia Z. Shalhout, Glenn J. Hanna, David M. Miller, Chrysalyne D. Schmults, Eleni M. Rettig, Ruth K. Foreman, Rosh K.V. Sethi, Manisha Thakuria, Ann W. Silk · 发表于：JAMA Otolaryngology–Head & Neck Surgery · 年份：2024 · DOI：10.1001/jamaoto.2024.0259 · 被引用次数：29 · 研究领域：Nonmelanoma Skin Cancer Studies、Cutaneous Melanoma Detection and Management、Cancer Immunotherapy and Biomarkers

Importance: In clinical trials, preoperative immune checkpoint inhibitors (ICIs) have shown clinical activity in advanced cutaneous squamous cell carcinoma (cSCC). However, these studies excluded patients with relevant comorbidities. Objective: To evaluate radiologic and pathologic response rates to neoadjuvant-intent programed cell death protein 1 (PD-1) ICIs in a clinical population. Design, Setting, and Participants: This cohort study of patients who were treated with neoadjuvant cemiplimab or pembrolizumab for advanced cSCC from January 2018 to January 2023 was conducted at 2 academic institutions in Boston, Massachusetts. Median follow-up was 9.5 months (range, 1.2-40.5). Exposures: Cemiplimab or pembrolizumab. Main Outcomes and Measures: Primary outcomes were radiologic and pathologic response rates. Secondary outcomes were 1-year recurrence-free survival, progression-free survival, disease-specific survival, and overall survival. Results: This cohort study included 27 patients (including 9 patients [33.3%] with a history of lymphoma). Most patients were male (18 of 27 [66.7%]), with a median age of 72 years (range, 53-87 years). Most primary tumors were located on the head/neck (21 of 27 [77.8%]). There were no unexpected delays in surgery. The median number of doses before surgery was 3.5 (range, 1.0-10.0). Five patients (18.5%) ultimately declined to undergo planned surgery due to clinical responses or stability, and 1 (3.7%) did not undergo surgery due to progressiv...